Jefferies Financial Group Inc. Takes Position in Pulmonx Corporation $LUNG

Jefferies Financial Group Inc. purchased a new position in shares of Pulmonx Corporation (NASDAQ:LUNG) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 285,110 shares of the company’s stock, valued at approximately $371,000.

Other large investors have also modified their holdings of the company. Cerity Partners LLC bought a new stake in Pulmonx in the 4th quarter valued at about $27,000. Opal Capital LLC bought a new position in Pulmonx in the 4th quarter worth about $29,000. Lazard Asset Management LLC acquired a new stake in shares of Pulmonx in the fourth quarter valued at approximately $31,000. Jain Global LLC acquired a new stake in shares of Pulmonx in the third quarter valued at approximately $30,000. Finally, R Squared Ltd bought a new stake in shares of Pulmonx during the first quarter valued at approximately $26,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on LUNG shares. Weiss Ratings upgraded Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 25th. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Pulmonx presently has a consensus rating of “Moderate Buy” and an average price target of $7.67.

Pulmonx Stock Performance

NASDAQ:LUNG opened at $2.38 on Tuesday. The company has a current ratio of 4.32, a quick ratio of 3.52 and a debt-to-equity ratio of 0.95. The firm has a market cap of $102.22 million, a price-to-earnings ratio of -2.05 and a beta of 0.28. Pulmonx Corporation has a twelve month low of $1.13 and a twelve month high of $2.89. The company has a 50-day moving average of $1.75 and a 200-day moving average of $1.54.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.04. The company had revenue of $22.76 million for the quarter, compared to analysts’ expectations of $22.39 million. Pulmonx had a negative return on equity of 96.66% and a negative net margin of 55.03%. Analysts forecast that Pulmonx Corporation will post -1.05 earnings per share for the current fiscal year.

Pulmonx Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.